Author name: DrugChatter

Why Pharmaceutical Companies Must Monitor AI Mentions Right Now There is a new drug representative calling on your patients and […]

How pharmaceutical brands are losing control of their narrative to AI answer engines — and the monitoring infrastructure they need

The Question Every Pharma Brand Team Is Ignoring Somewhere right now, a 54-year-old with newly diagnosed Type 2 diabetes is

What pharma’s regulatory, medical affairs, and brand teams need to do right now There is a scenario playing out across

Pharmaceutical brands are losing control of their product narrative — not in the press, not at the pharmacy counter, but

The Problem No One Is Watching Closely Enough Somewhere between a patient typing symptoms into a chatbot and a physician

Patients are asking ChatGPT about your drug. Physicians are consulting Gemini before prescribing. Regulators are building their own AI review

The Invisible Conversation Shaping Your Drug’s Reputation Somewhere right now, a patient is asking an AI chatbot whether their statin

How ChatGPT, Gemini, and a dozen other AI chatbots became the most unmonitored channel in pharmaceutical brand strategy — and

The medical information landscape has shifted from static search results to dynamic, generative responses. While pharmaceutical companies have spent decades

Audit ChatGPT for FDA Compliance Pharmaceutical companies face a new regulatory gap as patients and physicians turn to large language

The era of the ten-blue-link search result is ending. For pharmaceutical marketers, the transition from Google Search to Large Language